Introduction
============

Gene-editing technology has recently emerged as a new treatment modality for a variety of diseases, including hereditary, infectious, and neoplastic diseases. The remarkable progress in nuclease engineering has enabled accurate modification of the eukaryotic genome for therapeutic purposes^[@bib1],[@bib2]^. Gene-editing nucleases are restriction enzymes with engineered DNA-binding domains that produce double-stranded breaks (DSBs). The three major types of gene-editing nucleases, listed in order of their development, are zinc finger nuclease (ZFN)^[@bib3]^, transcription activator-like effector nuclease (TALEN)^[@bib4]^, and clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease Cas9 (CRISPR/Cas9)^[@bib5]^. The application of CRISPR/Cas9 to genome editing, in particular, has had a tremendous effect on the rate at which genetically engineered materials for gene therapy have been developed, owing to the simplicity of the manufacturing process, as compared with earlier generations of engineered nucleases, including ZFN and TALEN^[@bib6]^.

Gene-editing-based therapy has considerable merits compared with transient expression-modulating gene therapy^[@bib1],[@bib2],[@bib5]^. For inducing gene expression, functional genes have been delivered to target cells or tissues that lack specific functions. For decreasing gene expression, short nucleic acid sequences have been introduced to silence or interfere with the disease-related gene. However, both strategies have limitations, such as an incomplete therapeutic effect, owing to transient gene silencing and mutagenesis caused by incorrect gene insertion. In contrast, therapeutics based on gene-editing technology can exert permanent and elaborate proofreading effects at the genome level and thus represent a key development in gene therapy.

There are currently dozens of clinical studies of gene-editing-based therapeutics, including *in vivo* and *ex vivo* editing therapies. For the successful translation of gene-editing-based therapeutics to the clinic, efficient and safe delivery systems are indispensable^[@bib7]^. Various delivery systems^[@bib7],[@bib8],[@bib9]^ and electroporation techniques^[@bib10],[@bib11],[@bib12],[@bib13]^ have been studied to introduce gene-editing nucleases in the form of DNA^[@bib14],[@bib15],[@bib16],[@bib17],[@bib18]^, mRNA^[@bib19],[@bib20],[@bib21],[@bib22]^, or protein^[@bib23],[@bib24],[@bib25],[@bib26],[@bib27],[@bib28]^. Viral vectors used for *ex vivo* and *in vivo* delivery of nuclease-encoding genes include adeno-associated virus^[@bib29],[@bib30],[@bib31],[@bib32],[@bib33]^, adenovirus^[@bib34],[@bib35],[@bib36],[@bib37]^, and lentivirus^[@bib38],[@bib39],[@bib40],[@bib41],[@bib42]^. Additionally, non-viral delivery systems, lipid-based nanoparticles^[@bib24],[@bib25],[@bib43],[@bib44],[@bib45],[@bib46],[@bib47],[@bib48]^, polymeric nanoparticles^[@bib49],[@bib50],[@bib51],[@bib52]^, and cell-penetrating peptides^[@bib26],[@bib27]^ have been investigated.

Currently, there are several guidelines for gene-based therapeutics and cell therapies. These guidelines cover quality control^[@bib53],[@bib54],[@bib55],[@bib56]^, safety^[@bib56],[@bib57],[@bib58],[@bib59]^, and efficacy^[@bib54],[@bib59],[@bib60],[@bib61]^ issues of gene-based therapeutics and may provide a basis for regulatory considerations regarding the evaluation of gene-editing therapeutics. Despite the rapid progress and clinical significance of gene-editing technology, explicit regulatory guidelines focusing on the preclinical and clinical evaluation of gene-editing therapeutics are not yet available. In this review, we address the strategies for delivering gene-editing-based therapeutics and consider the regulatory aspects of nuclease delivery systems.

Gene-editing nucleases
======================

Gene-editing nucleases ([Figure 1](#fig1){ref-type="fig"}) are composed of a target-sequence-recognizing domain (guide RNA, in the CRISPR/Cas9 system) and a nuclease^[@bib1]^. After the programmed nuclease cleaves the target gene, repair of DSBs proceeds through two different mechanisms: non-homologous end joining (NHEJ) and homology-dependent repair (HDR). NHEJ, which eliminates the target region by joining DSBs, can be utilized to silence or correct a pathogenic gene, whereas HDR can introduce a homologous sequence into DSBs, enabling donor DNA to be inserted to either correct an existing gene or add a new one. The properties of gene-editing nucleases and the differences among them are summarized in [Table 1](#tbl1){ref-type="table"}.

ZFN ([Figure 1A](#fig1){ref-type="fig"}) contains a Cys~2~-His~2~ zinc finger and *Fok*I nuclease as the DNA-binding and cleavage domains, respectively^[@bib62]^. Because each zinc finger module (∼30 amino acids) recognizes a specific 3-base-pair DNA sequence, several zinc finger modules are typically engineered on the basis of the target sequence. After the binding of zinc finger modules to target DNA, the *Fok*I restriction enzyme mediates DNA cleavage. In general, if more than three modules are engineered, symmetrical *Fok*I dimerization is required for increased target specificity and cleavage efficiency. Although zinc fingers have demonstrated their potential as genetic \'scissors\' in mammalian cells, the strategy is limited because the selected target region must meet the requirement of a 5′-GNNGNNGNN-3′ motif. Engineering a zinc finger module for each target gene is also expensive and time consuming.

TALEN ([Figure 1B](#fig1){ref-type="fig"}), like ZFN, also utilizes *Fok*I nuclease as a cleavage domain^[@bib4]^. The DNA-binding domain, TALE, which originates from the plant pathogen *Xanthomonas campestris*, contains 34--35 amino acids per module, two of which, termed repeat-variable di-residues, determine the specific DNA base pair recognized. The recognition of a single DNA base pair by one TALE module is beneficial in terms of selecting the target regions; however, the complicated engineering procedures required for the recognition of a wider range of target gene sequences have been a matter of concern. To solve the problem, researchers have developed a TALEN plasmid library that recognizes 14--18 base pairs and can target 18 742 human genes^[@bib63]^.

The CRISPR/Cas9 system ([Figure 1C](#fig1){ref-type="fig"}) is based on a prokaryotic antiviral mechanism in which bacteria insert a partial gene sequence from an infection source, such as a bacteriophage, into their own genomes to defend against repeat infection^[@bib64]^. Specifically, CRISPR/Cas9 uses a guide RNA to bind a complementary sequence in a target gene, after which Cas9 recognizes and cuts the target DNA. The CRISPR/Cas9-based system has revolutionized gene editing, and the DNA-binding function of short guide RNA offers the potential for the rapid development of gene-editing-based therapeutics as simplefacile designs of singleguide RNA (sgRNA) design tools and multiplexing ability (several target DNAs in the same cells) become available^[@bib65]^.

*In vivo* and *ex vivo* gene editing
====================================

Therapeutic gene editing can be administered through two basic strategies: (1) direct in vivo delivery of a gene-editing nuclease and (2) delivery of cells engineered *ex vivo* to contain a gene-editing nuclease ([Figure 2](#fig2){ref-type="fig"})^[@bib1]^. Appropriate delivery systems for *in vivo* gene editing include viral vectors and cationic lipid- or polymer-based non-viral vectors, because the cargo for gene editing usually involves a plasmid vector or mRNA encoding the gene-editing nuclease. Occasionally, naked plasmids have been locally injected into particular tissues, such as eye and muscle. Because systemic injection of gene-editing nucleases can drive gene modifications in multiple tissues, depending on the delivery strategy, the benefits of gene editing can be more readily extended to various diseases, as compared with *ex vivo* gene editing. Similarly, the tissue-wide distribution associated with *in vivo* delivery raises the issue of tailoring the biodistribution and pharmacokinetic profiles of gene-editing delivery carriers to minimize side effects in off-target tissue. *Ex vivo* gene editing requires a somewhat complicated procedure for *ex vivo* genetic modifications before transplantation. Removal of target cells from the patient is the first step in using an *ex vivo* strategy to deliver gene-editing nucleases. Viral vectors have been favored for the delivery of gene-editing systems to hard-to-transfect cells, such as immune cells and stem cells. Moreover, stimulus-based strategies, such as electroporation and magnetofection, are possible for *ex vivo* gene editing, because the selection of a delivery vector for this type of gene editing is not affected by the behavior of the vector *in vivo* ([Table 2](#tbl2){ref-type="table"}).

Current strategies for the delivery of gene-editing therapeutics
================================================================

Gene-editing-based therapy has been actively studied for investigational and non-clinical development ([Figure 3](#fig3){ref-type="fig"}). The majority of these studies have been conducted in the United States (54.4%), and the next highest percentage of studies (19.1%) have been conducted in China ([Figure 3A](#fig3){ref-type="fig"}). Viral infection (33%), blood disease (19%), and neoplasms (13%) have been the major disease targets of therapeutic gene editing ([Figure 2](#fig2){ref-type="fig"}). Although CRISPR/Cas9-mediated gene editing is the most recently developed gene-editing tool, it has been the most widely investigated both in vitro and in vivo, owing to its convenience and accessibility ([Figure 3D](#fig3){ref-type="fig"}).

The delivery strategies for gene editing are divided into viral and non-viral vector systems ([Figure 4](#fig4){ref-type="fig"}). Unlike traditional gene therapy methods, non-viral vector-based studies have predominated (70%) over viral vector-based studies in investigations of gene-editing therapies ([Figure 4A](#fig4){ref-type="fig"}), because electroporation, a non-viral method, is the main approach utilized for ex vivo gene editing (39% of all reports). In the case of viral vectors, lentiviruses are most often used, followed by adenovirus-associated virus (AAV) and adenovirus, respectively ([Figure 4B](#fig4){ref-type="fig"}). After electroporation, which is by far the most important non-viral method for ex vivo gene delivery (56%), the next most common delivery methods are based on lipids (17%) and polymers (8%) ([Figure 4C](#fig4){ref-type="fig"}).

Lentiviral vectors have the advantage of being able to integrate into dividing and non-dividing cells; they also have a relatively large capacity (∼8 kb), thus facilitating the delivery of large nuclease-coding sequences^[@bib66]^. Lentiviral vectors have traditionally been used for the transfer of gene-editing components into hard-to-transfect cells, such as T cells^[@bib38],[@bib39],[@bib67]^ and primary cells^[@bib38],[@bib68],[@bib69]^, which are used to treat human immunodeficiency virus (HIV) infections and neuromuscular disease, among others. Compared with adenoviruses, AAVs are less pathogenic and non-immunogenic and are thus suitable for *in vivo* gene editing to exert influences throughout the body^[@bib70]^. Indeed, most approaches that have used AAV delivery systems have been applied to investigate *in vivo* gene editing in animals.

Among the non-viral delivery systems, electroporation, a traditional gene-transfer method, is the most effective in delivering genetic materials and thus exhibits high transfection efficacy in hard-to-transfect cells^[@bib7]^. However, this method has limitations for direct application *in vivo*, including cytotoxicity and immune-stimulating effects. Therefore, electroporation has been widely used for *ex vivo* gene editing of immune cells, stem cells, and primary cells^[@bib10],[@bib14],[@bib19]^. Lipid- or polymer-based non-viral vectors, compared with viral delivery vectors, are relatively safer *in vivo* and can be modified in various ways for target-cell-specific delivery^[@bib71]^. Because cationic liposomes or polymers usually load nucleic acid cargo via electrostatic interactions, they enable various types of gene-editing components, such as mRNAs and short RNAs, to function immediately in the cytoplasm after cellular entry.

Clinical trials of gene-editing-based therapeutics
==================================================

Currently, 18 gene-editing-based therapeutics are undergoing clinical trials worldwide ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)) as depicted in [Figure 5](#fig5){ref-type="fig"}. ZFN-based approaches, with 11 trials (6 of which are organized by Sangamo Bioscience), represent the majority (61%) of these clinical studies. Among the trials using ZFNs, three are Phase I/II trials targeting the *CCR5* (C--C motif chemokine receptor 5) gene for HIV infection. The remaining eight ZFN studies are Phase I trials varying in terms of target gene, disease, and delivery strategy. In the case of TALEN trials, three Phase I trials of multiplex gene editing targeting *TCRa* (T cell receptor a) and *CD52* to improve the efficacy of chimeric antigen receptor (CAR)-modified T cells targeting CD19 (CD19-CAR-T; UCART19, licensed to Servier) are currently underway. The most recently developed CRISPR/Cas9 system has recently been used in clinical trials in China designed to knock out *PDCD1*(programmed cell death protein 1) as a treatment for multiple cancers.

The gene-editing delivery strategies used in clinical trials can be classified into three categories: viral vectors (6 studies), electroporation (6 studies), and naked plasmids (1 study) ([Table 3](#tbl3){ref-type="table"}). The *ex vivo* gene-editing strategies targeting CCR5 to inhibit HIV entry use adenoviral vectors (4 studies) or the electroporation method (3 studies) for T cell transfection. Electroporation of TALEN mRNA (3 studies) has also been used for *TCRa/CD52* knockout in the trials of CD19-CAR-T. Although information on vectors is not yet available for the four trials using *ex vivo* CRISPR/Cas9 gene editing, viral vectors or electroporation methods are presumably used on the basis of their efficient T cell transfection. *In vivo* administration of AAV vectors has also been used in hepatocyte-targeted gene-editing therapy for the treatment of hemophilia B and MPS I. A *CCR5*-knockout T cell line (SB-728-T), a leading therapeutic gene-editing candidate, has been constructed by adenoviral delivery of ZFN^[@bib95]^. In a Phase I safety study (NCT00842634), 12 HIV-infected patients received a single infusion of 5×10^9^--10×10^9^ *CCR5*-knockout T cells. The blood concentration of SB-728-T was consistently maintained, exhibiting a mean half-life of 48 weeks (loss rate, 1.81 cells/d). In comparison, the loss rate of the unmodified T cells was 7.25 cells per day. In the preliminary stage of a Phase II trial, an adenoviral delivery strategy also induced additional CD8-mediated immune stimulation, thus suggesting an adjuvant-like effect of the adenovirus used for gene editing.

Regulatory perspectives
=======================

With the growing number of studies investigating gene-editing-based therapeutics comes the need to address regulatory concerns that might affect clinical applications^[@bib54],[@bib60],[@bib96]^. Although it is not possible to clearly outline all the potential regulatory concerns relevant to gene-editing-based therapeutics, the major issues include safety, efficacy, and quality control. In fact, the genetic materials for delivery of gene-editing nucleases are not markedly different from those for conventional *ex vivo*/*in vivo* gene therapies. Thus, quality control and efficacy evaluations of *in vivo* gene-editing therapeutics can be considered in the context of existing gene-therapy guidelines^[@bib54],[@bib55],[@bib56],[@bib57],[@bib58],[@bib59],[@bib60],[@bib61],[@bib97]^. Similarly, existing gene/cell therapy guidelines can be applied to *ex vivo* gene-editing therapeutics. The existing guidelines relevant for gene-editing therapeutics issued by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are summarized in [Table 4](#tbl4){ref-type="table"}. However, novel gene-editing mechanisms using exogenous nucleases raise significant new safety concerns.

Gene-editing-based therapeutics introduce a new degree of complexity to delivery methods and delivery systems^[@bib98]^. Depending on the mode of delivery, the risk levels and concerns can vary^[@bib99]^. Overall, the risk is higher for direct *in vivo* delivery compared with *ex vivo* delivery of gene-edited cell therapeutics. The delivery system itself can also affect risk levels. The use of viral vectors, compared with proteins or mRNAs delivered through non-viral vectors or electroporation, may raise greater safety concerns. Because of the high risks associated with *in vivo* gene editing at the current stage of development, most gene-editing-based therapeutics currently in clinical trials use the *ex vivo* gene editing strategy. In this review, we will focus greater attention on the *ex vivo* delivery form of gene-editing therapeutics.

Safety
------

Safety is the most important issue from a regulatory perspective. The working mechanism of nuclease-mediated genome editing presents a double-edged sword: whereas it provides a therapeutic effect that is unprecedented in its power, it also bears major safety concerns^[@bib100]^. Because gene-editing therapeutics act by creating DSBs in genomic DNA, the risks of off-target toxicity at unintended sites are higher than those associated with other gene therapeutics that do not induce chromosomal insertions or genome alterations. Moreover, unlike chemicals and antibody-based drugs, the genome-level action of gene-editing therapeutics evokes concerns about the selection of relevant animal models for safety studies. For *in vivo* gene-editing therapeutics, the binding specificity of the designed nucleases is governed by specific sequences in the genome. Because the mouse genome has substantial differences compared with the human genome, preclinical safety studies, especially for *in vivo* gene-editing therapeutics, should be conducted in humanized animal models that mimic the human genome.

### Off-target genotoxicity

Although the engineered nucleases possess a targeting specificity for accurate gene editing, unintended interactions of the nucleases and the consequent cleavage of non-target sites nonetheless occur^[@bib101]^. "Off-target" genotoxicity can be defined as toxic side effects caused by unintended gene cleavage at non-target sites. The CRISPR/Cas9 system has a relatively higher chance of generating such \'off-target\' cleavages, because sgRNA can bind a mismatched sequence with a partial complementation. The off-target effect has been regarded as a major concern for clinical application of gene editing therapeutics. Because gene-editing technology, by nature, modifies the genome, the most important safety issue is the possibility of genotoxicity through the modification of non-target genes^[@bib101]^. Alterations of the genome at non-target loci are classified primarily as large-scale translocations or deletions and small-scale insertions/deletion (indels). A variety of appropriate methods are available for studies designed to test the occurrence of large- and small-scale off-target genotoxicity. Functional studies of gene-edited cells would be suitable for initial off-target genotoxicity studies. These functional studies could include an examination of changes in the viability, proliferation, and cell-cycle behavior of gene-edited cells.

If no changes in the functional behavior of the gene-edited cells are observed, the next step would be to test for large- and small-scale off-target effects. Large-scale genomic changes include translocation, deletion, and inversion^[@bib70]^. These large-scale genomic changes can be detected by using array comparative genomic hybridization techniques and genotyping in gene-edited cells used in *ex vivo* therapeutics or in biopsied cells from *in vivo* therapeutic applications.

If no evidence of large-scale gene modification is found, the next step would be to test small-scale indel frequencies at off-target loci. In silico surveys, whole-exome profiling, and whole-genome profiling can be used to test the occurrence of off-target indels in gene-edited therapeutics. Whole-exome profiling can reveal changes in the exons encoding all proteins and should be performed for any delivery form. Recently, whole-exome profiling has been used to test the off-target effects of CRISPR/Cas nucleases^[@bib102]^. DNA fragments derived from viral vectors or plasmid DNA, compared with proteins or mRNA delivered using non-viral vectors or electroporation, may have higher risks of insertion into DSBs at off-target sites.

Thus, whole-genome profiling may be a necessary adjunct for applications in which nucleases are delivered by viral vectors or plasmid DNA. For genome-wide profiling, Guide-seq^[@bib103]^ and Digenome-seq^[@bib104]^ systems have been used to assess off-target cleavage by CRISPR/Cas nucleases. A T7 endonuclease 1 cleavage assay has also been used to verify small-scale off-target indels and mutations introduced by CRISPR/Cas nucleases^[@bib105]^.

Gene-editing therapeutics use several pathways for editing genes, each with its own benefits. After the cleavage of genomic DNA by ZFN, TALEN or CRISPR/Cas9, the resulting DSBs are repaired by either NHEJ or HDR mechanisms. In the latter mechanism, both crossover and non-crossover pathways are possible. If NHEJ is the major pathway, indels and mutations may be the predominant genotoxicities. If HDR and gene addition are the major pathways, the possibility of off-target insertion should be carefully monitored.

Recent studies have reported that the frequency of small-scale indels varies depending on cell type^[@bib106]^. For comparison with other studies and for evaluating the consistencies of gene-editing techniques, the frequencies of small-scale indels must be quantified for both *ex vivo* gene-edited cells and *in vivo*-biopsied cells.

### Immunogenicity

The immunogenicity of gene-editing therapeutics is an important consideration that must be assessed regardless of the delivery method and nuclease type. ZFN, TALEN, and CRISPR/Cas9 are all exogenous and foreign to the human body. Notably, intracellular processing and presentation of these antigens by major histocompatibility molecules have not yet been studied. However, given the foreign nature of bacterial nucleases such as TALEN and CRISPR/Cas9, the induction of antibodies against these nucleases should be investigated^[@bib107]^. In addition to inducing humoral immune responses, the presentation of antigens derived from these foreign nucleases with major histocompatibility complex I molecules on gene-edited cell surfaces may also evoke T-cell immune responses. Moreover, the possibility of autoimmunity to autologous and gene-edited cell therapeutics should be addressed.

When viral vectors are used for *in vivo* gene editing, the development of antibodies and T-cell immune responses against the viral vectors can limit the repeated use of the same viral vectors^[@bib108]^. Indeed, the possibility of host immune responses caused by the bacterial origin of CRISPR/Cas9 proteins and viral vectors has been suggested to be one of the hurdles for the use of *in vivo* gene editing in viral-vector-based therapy^[@bib109]^. AAV vectors have been most widely used in gene editing, because AAV vector was authorized for the delivery of Glybera, the first approved gene therapeutic in Europe. However, previous studies have shown that AAV vectors can induce antibodies and T-cell responses^[@bib110],[@bib111]^; impurities in viral vector preparations, such as host cell proteins and other contaminants, can also influence the immunogenicity of the recombinant viral vectors that encode nucleases^[@bib112]^. In addition, the virus capsid protein along with prolonged expression of the encoded nucleases after the delivery of *in vivo* viral-vector-based gene-editing therapeutics can induce antibodies and T-cell immune responses. Although non-viral vectors such as polymeric nanoparticles and lipid nanoparticles are considered to be less immunogenic than viral vectors^[@bib109]^, the immunogenicity of the expressed nucleases should also be studied, as should the induction of antibodies against the proteins or peptides assembled within the nanoparticles that are used for *in vivo* non-viral delivery of nucleases and guide RNA.

### Pharmacokinetics and biodistribution

The pharmacokinetics of gene-editing therapeutics may differ between *ex vivo* and *in vivo* strategies^[@bib113],[@bib114]^. For *ex vivo* gene-editing therapeutics, pharmacokinetic studies of the time-dependent profiles of gene-edited cells must be performed. In addition to the level of gene-edited cells in the blood, the DNA levels of the gene-modified segments should be monitored through quantitative polymerase chain reactions. For *in vivo* gene-editing therapeutics, the form of the delivery system is expected to affect the pharmacokinetic profile. If viral vectors are used for the *in vivo* delivery of gene-editing nucleases, the pharmacokinetic profiles of the vectors should be traced by using relevant markers and by monitoring the encoded nuclease gene^[@bib115]^. If protein forms of the nucleases are used for their *in vivo* delivery, levels of the protein nucleases should be monitored in the blood possibly by using enzyme-linked immunosorbent assays^[@bib116]^. If mRNA or naked plasmid DNA is used for the *in vivo* delivery of nucleases via electroporation, the introduced forms of nuclease-encoding nucleic acids in the blood should also be quantified.

Studies of the *in vivo* distribution of *ex vivo* gene-editing therapeutics must address two aspects: the *in vivo* fate of the gene-edited cells and the distribution of nucleases used for gene modification. If *ex vivo* modifications are performed with protein forms of the nucleases, the distribution of nuclease protein levels would be relevant. If *ex vivo* modifications are performed with the mRNA form of nucleases, distribution studies would be best performed by following mRNA and protein levels in each organ. Moreover, if *ex vivo* modifications are performed with the DNA form of nucleases, distribution studies should investigate the DNA levels. Finally, if the *ex vivo* modification is performed with a viral vector encoding nuclease DNA, the persistence of foreign nuclease DNA in the body should be studied as well.

The *in vivo* distribution of *in vivo* gene-editing therapeutics may require more extensive investigations, owing to the systemic circulation of nucleases administered by various delivery vectors^[@bib57],[@bib58],[@bib117]^. Currently, one of the major target diseases of gene-editing therapeutics is cancer. Thus, it would be important to know the target distribution and gene-editing effects of nucleases in cancer tissues. However, the distribution and modification of genes in normal tissues by systemically injected nucleases may cause severe side effects. Especially in cases where *in vivo* gene editing is performed with viral vectors encoding nucleases and additional genes, distribution studies should test the DNA levels of nucleases and inserted genes in all organs and germ cells.

### Tumorigenicity

The tumorigenicity of gene-edited therapeutics is an important aspect that must be investigated. Gene-modified CD34^+^ cells transduced with a retroviral vector carrying a gene encoding interleukin-2 receptor gamma have been clinically studied for the treatment of X-linked severe combined immunodeficiency. In that study, the retrovirus inserted itself near proto-oncogenes, thus resulting in the development of T-cell leukemia in four patients^[@bib118]^. The potential tumorigenicity of induced pluripotent stem cells is considered to be one of the major hurdles for stem cell therapies^[@bib119]^. In the case of induced pluripotent stem cells, retroviral gene insertion has been discussed as one of the factors that contribute to tumorigenicity. These studies have raised concerns about the tumorigenicity risks of insertional gene modifications at off-target sites. Therefore, strong evidence for the lack of tumorigenicity needs to be provided by using animal models before initiation of clinical trials. The use of Onco-chip^[@bib120]^ to screen for changes in oncogenic protein expression would provide relevant supplementary data.

### Safety of delivery systems

The safety of delivery systems for nucleases and other components of gene-editing systems should be studied separately^[@bib121]^. For *in vivo* gene-editing viral vectors, in addition to immunogenicity, chromosomal integration and duration of expression should be monitored. The possibility of viral shedding in the cases in which viral vectors are used for *in vivo* gene-editing therapeutics must be carefully addressed. For viral vectors that are capable of gene editing, sexual transmission to spouses may cause unwanted gene editing. Moreover, the germline transmission of viral vectors should also be monitored.

Although the safety profiles of polymer- or lipid-based non-viral nanoparticles are more favorable because they do not insert into chromosomes and because they exhibit shorter *in vivo* half-lives than viral vectors, the relevant *in vivo* toxicities and inflammation issues must be addressed. In the case of physical device-based delivery methods, such as electroporation, risk factors such as device-mediated infection, inflammation, and tissue damage should be considered.

### Efficacy

Depending on the purpose and disease target, the models used to demonstrate the efficacy of gene-editing therapeutics may vary. However, similarly to procedures used to address safety concerns, efficacy studies should use humanized animal models. Factors that should be considered in efficacy studies include, at minimum, the selection of dose, establishment of relevant animal disease models, efficiency of gene editing, and duration of efficacy^[@bib1]^.

### Dose units

Unlike chemical drugs, for which doses can be similarly expressed in grams, the dose units for different gene-editing therapeutics may differ depending on the type of delivery method. For *ex vivo* gene-editing therapeutics, the population of gene-edited cells among the total injected cells should be determined^[@bib95]^. For *in vivo* gene-editing therapeutics, the injection dose may vary depending on the form in which nucleases are delivered. In cases in which nucleases are delivered in protein, mRNA, or plasmid DNA forms, the therapeutic effects should be studied on the basis of the administered dose in grams of protein or nucleic acid per body weight. In the case of nucleases delivered by viral vectors, the therapeutic effects should be studied on the basis of the administered doses according to viral titers.

### Dose-efficacy correlation

Unlike chemical drugs, which generally show gradually increasing dose effects until a saturating dose is reached, gene-editing therapeutics may show rapid turn-on or turn-off effects over narrow dose ranges. As seen in the case of recently emerging RNA interference (RNAi)-based drugs that act at the mRNA level, rapid degradation of siRNA in the cytoplasmic environment necessitates high doses of injected siRNA. However, the action of gene-editing therapeutics at the genome level may result in an increase in potency, given that a single correction of the genome may result in perpetual correction of cellular protein levels^[@bib1]^. Indel-based *ex vivo* gene-editing therapeutics may have \'on\' or \'off\' effects depending on the occurrence of DSBs at the target locus. Thus, the efficacy of gene-editing therapeutics should be studied at various dose units, depending on the method of nuclease delivery.

### Efficiency of gene editing

The efficiency of gene editing must be quantified statistically. The efficiency of NHEJ- and HDR-mediated DSB repair is known to vary according to cell type and cell state^[@bib1]^. Additionally, the efficiency of HDR-mediated gene addition has been reported to depend on the selected target gene^[@bib122]^. Quantification of gene-editing efficiency would be helpful in comparing the efficiency of various vectors and standardizing the relationship between editing efficiency and therapeutic efficacy. Currently, the efficiency of *in vivo* HDR is known to be low^[@bib123]^.

### Duration of gene editing

Spontaneous mutations and instability of the genome may abrogate the therapeutic effects of gene editing. The duration of gene deletion, site-specific correction, or insertion at the target locus after treatment with gene-editing therapeutics should be monitored over months^[@bib124]^. Especially in the case of *in vivo* viral-vector-based gene-editing therapeutics, the prolonged expression of nucleases in the body can reintroduce DSBs at nearby target sites and lead to instability^[@bib125]^. The duration of gene editing should thus be more carefully monitored in the case of *in vivo* viral-vector-based gene-editing therapeutics.

### Animal models for efficacy tests

Compared with chromosome-insertional viral-vector-based gene therapy, gene editing-based therapeutics have a novel ability to elaborately and controllably modify the genome by recognizing target gene sequences for deletion or insertion. In principle, humanized animal models should be used for studying the on-target efficacy of gene-editing therapeutics. Because the establishment of humanized animal models other than rodents may be difficult, non-human primates might be used, although their genomes differ from the human genome. When non-human primates are used as large animal models, in silico-based studies should be conducted to validate the similarity of target gene sequences between primates and humans^[@bib124]^.

### Quality control

Quality control of gene-editing therapeutics may not differ substantially from existing guidelines on gene therapeutics and gene-modified cell therapeutics. The quality control-related guidance for gene and cell therapeutics issued by the FDA and EMA are summarized in [Table 4](#tbl4){ref-type="table"}. The main factors to consider for quality control include purity and the absence of microbial contamination and endotoxins. Especially in the case of *ex vivo* gene-editing therapeutics, the viability and fraction of gene-modified cells must be controlled.

### Characterization

For *ex vivo* gene-editing therapeutics, the phenotypes of gene-edited cells should be characterized by using relevant markers. For *in vivo* gene-editing therapeutics, delivery vectors should be physicochemically characterized, and especially when non-viral chemical vectors are used, the sizes, zeta potentials, and nuclease/vector ratios must be determined^[@bib59],[@bib60],[@bib126]^.

### Purity

For *ex vivo* gene-editing therapeutics, consistent amounts of gene-edited cells should be produced with minimal batch-to-batch variations. Currently, autologous cells are isolated for *ex vivo* gene-editing therapeutics and are injected back into patients. However, transfection and gene-editing efficiencies may vary depending on the age and health of the individual. The ranges of acceptable gene-edited cell populations among total cells should be determined on the basis of statistical analysis of a sufficient number of patients^[@bib124]^. For *in vivo* gene editing, therapeutics using viral vectors for delivery of nuclease genes should be tested for purity. Regardless of the *ex vivo* or *in vivo* gene-editing strategy, the injectable forms should be free of endotoxins.

### Sterility of gene-editing therapeutics

For *ex vivo* gene-editing therapeutics, autologous cells are harvested, and nucleases and other gene-editing components such as single guide RNA, are introduced, after which the gene-edited cells are administered back into patients. Because the cells for *ex vivo* gene-editing therapeutics are processed outside the body, microbial studies should be performed. In the case of *in vivo* gene-editing therapeutics, viral vectors should be tested and shown to be free of pathogenic microbial and mycoplasma contamination^[@bib55],[@bib124]^.

### Viability of ex vivo therapeutics

In the case of *ex vivo* therapeutics, the viability of the gene-edited cells should be tested and consistently monitored. For this purpose, viability studies capable of differentiating gene-edited cells from non-edited cells in the total cell population should be designed and used^[@bib53],[@bib124]^.

### Manufacturing processes

The process for manufacturing gene-editing therapeutics should be validated to ensure the sterility and consistency of products^[@bib54],[@bib56],[@bib124]^. For *ex vivo* gene-editing therapeutics, the procedure for isolating cells from patients, transduction of the cells with gene-editing delivery systems, and cultivation of the gene-edited cells should be validated. Additionally, quality assurance assays should be performed. For *in vivo* viral vector-based gene-editing therapeutics, the processes for amplifying, purifying, identifying, and quantifying viral vectors should be validated. For *in vivo* non-viral vector-based gene-editing therapeutics, the acceptable size ranges of non-viral vectors, nuclease loading, and processes for identifying nuclease-loaded non-viral vectors must be validated.

Conclusions
===========

Gene editing is a rapidly growing technology in the overall field of biotechnology, thus reflecting its potential as an innovative genetic manipulation tool. Indeed, gene-editing therapy has attracted substantial interest from international pharmaceutical companies and has undergone a profusion of clinical trials within a relatively short period. Although gene-editing therapeutics have undergone remarkable progress, considerations of regulatory issues have not kept up with the pace of development. For clinical applications, safety issues should be thoroughly considered on the basis of gene-editing strategies, including *ex vivo*/*in vivo* methods, type of genetic materials, and delivery vectors. Given the potential for off-target genotoxicity and other crucial considerations, the release of new regulations tailored to gene-editing therapeutics would facilitate the development of this potent new treatment modality from bench-to-bedside.
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![Gene-editing nucleases. Gene-editing nucleases include ZFN (A), TALEN (B), and CRISPR/Cas9 (C).](aps20172f1){#fig1}

![Therapeutic gene-editing strategies. A schematic depiction of *in vivo* and *ex vivo* gene editing is shown. For *in vivo* gene editing, viral or non-viral vectors carrying nucleases are directly injected into the body. For *ex vivo* gene editing, the target cells are isolated and gene-edited with viral or non-viral vectors carrying nucleases, after which gene-edited cells are expanded and reinfused into the body.](aps20172f2){#fig2}

![Current status of gene-editing studies in non-clinical development. Therapeutic gene editing in non-clinical development, analyzed by country (A), target disease (B), editing type (C), and nuclease type (D).](aps20172f3){#fig3}

![Delivery strategies for gene-editing studies in non-clinical development. Therapeutic gene editing in non-clinical development, analyzed based on delivery strategy (A), viral vector type (B), and non-viral type (C).](aps20172f4){#fig4}

![Current status of therapeutic gene editing clinical trials. Clinical studies of therapeutic gene editing, analyzed by phase (A), country (B), delivery vector (C), editing strategy (D), nuclease type (E), and target gene (F).](aps20172f5){#fig5}

###### Properties of standard gene-editing nucleases.

                                       ZFN                                                                                     TALEN                                                                                        CRISPR/Cas9
  ------------------------------------ --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  DNA binding                          Zinc finger protein                                                                     TALE protein                                                                                 Guide RNA
  DNA cleavage DNA recognition range   *Fok*I 18--36 bp (3 bp/Zinc finger module)                                              *Fok*I 30--40 bp (1 bp/TALE module)                                                          Cas9 22 bp (DNA-RNA base pairing)
  Recognition sequence                 Sequence containing G base as follows: 5′-GNNGNNGNN-3′                                  Sequence starting from 5′-T and ending with A-3′                                             Sequence immediately followed by an adjacent protospacer motif 5′-NGG-3′
  Advantages                           Sequence-based module engineering Small protein size (\<1 kb)                           High specificity Accurate recognition by 1 bp Relatively easy selection of target region     Free selection of target region Simple synthesis of guide RNA Multiplexing ability
  Limitations                          Difficult sequence selection and zinc finger engineering Expensive and time-consuming   Not applicable to methyl cytosine Expensive and time-consuming Large protein size (\>3 kb)   Large protein size (\>4 kb)

###### *In vitro* and *in vivo* gene-editing studies in non-clinical development.

  Vector                        Target gene                 Disease                                          Nuclease             Material type of nucleases   In/Del   *In vitro/In vivo*   Organization                                           Country       Ref
  ----------------------------- --------------------------- ------------------------------------------------ -------------------- ---------------------------- -------- -------------------- ------------------------------------------------------ ------------- ------------
  Lentiviral vectors            CXCR4                       HIV                                              CRISPR/Cas9          DNA                          Del      *In vitro*           Wuhan University                                       China         ^[@bib38]^
                                HBV S, X                    HBV                                              CRISPR/Cas9          DNA                          Del      *In vitro*           Heinrich Pette Institute                               Germany       ^[@bib40]^
                                MSRB1                       HIV                                              CRISPR/Cas9          DNA                          Del      *In vitro*           Temple University                                      USA           ^[@bib39]^
                                ICP0                        HSV                                              CRISPR/Cas9          DNA                          Del      *In vitro*           Temple University                                      USA           ^[@bib41]^
                                RUNX2                       Osteosarcoma                                     CRISPR/Cas9          DNA                          Del      *In vitro*           National Cancer Institute                              USA           ^[@bib42]^
                                HIV long terminal repeats   HIV                                              CRISPR/Cas9          DNA                          Del      *In vitro*           Temple University                                      USA           ^[@bib72]^
                                CCR5                        Duchenne muscular dystrophy                      ZFN                  DNA                          In       *In vivo*            Université de Montréal                                 Canada        ^[@bib69]^
  Adenoviral vectors            CCR5                        HIV                                              CRISPR/Cas9          DNA                          Del      *In vitro*           Chinese Academy of Sciences                            China         ^[@bib34]^
                                HBB                         Sickle cell disease                              CRISPR/Cas9          DNA                          In       *In vitro*           University of Alabama at Birmingham                    USA           ^[@bib35]^
                                CXCR4                       HIV                                              ZFN                  DNA                          Del      *In vivo*            The Scripps Research Institute                         USA           ^[@bib36]^
                                CCR5                        HIV                                              ZFN                  DNA                          Del      *In vivo*            Beckman Research Institute                             USA           ^[@bib37]^
  Lentivirus and adenovirus     DMD                         Duchenne muscular dystrophy                      TALEN                DNA                          Del      *In vitro*           Leiden University Medical Center                       Netherlands   ^[@bib73]^
  AAV                           MIR137                      Neurological disorders                           CRISPR/Cas9          DNA                          Del      *In vivo*            University of North Carolina at Chapel Hill            USA           ^[@bib29]^
                                DMD                         Duchenne muscular dystrophy                      CRISPR/Cas9          DNA                          In/Del   *In vivo*            Harvard University                                     USA           ^[@bib30]^
                                OTC                         Hyperammonemia                                   CRISPR/Cas9          DNA                          In/Del   *In vivo*            University of Pennsylvania                             USA           ^[@bib31]^
                                F9                          Hemophilia B                                     ZFN                  DNA                          In/Del   *In vivo*            Children\'s Hospital of Philadelphia                   USA           ^[@bib32]^
                                G6Pase                      Glycogen storage disease type IA                 ZFN                  DNA                          In/Del   *In vivo*            Duke University                                        USA           ^[@bib33]^
  Electroporation               CFTR                        Cystic fibrosis                                  CRISPR/Cas9          DNA                          In       *In vitro*           The Salk Institute of Biological Studies               USA           ^[@bib10]^
                                ASXL1                       Chronic myeloid leukemia                         CRISPR/Cas9          DNA                          In/Del   *In vivo*            Oxford University Hospital                             UK            ^[@bib15]^
                                HBB                         β-Thalassemia                                    CRISPR/Cas9, TALEN   DNA                          In/Del   *In vitro*           Chinese Academy of medical Sciences                    China         ^[@bib11]^
                                p17                         HIV                                              TALEN                DNA                          Del      *In vitro*           Kyoto Prefectural University of Medicine               Japan         ^[@bib16]^
                                Rho                         Retinitis pigmentosa                             CRISPR/Cas9          DNA                          In/Del   *In vivo*            Cedars-Sinai Medical Center                            USA           ^[@bib17]^
                                GGTA1, CMAH                 Acute humoral xenograft rejection                CRISPR/Cas9          DNA                          Del      *In vitro*           Indiana University School of Medicine                  USA           ^[@bib18]^
                                ACVR1                       Fibrodysplasia ossificans progressiva syndrome   CRISPR/Cas9          DNA                          Del      *In vitro*           Korea Institute of Oriental Medicine                   Korea         ^[@bib14]^
                                FMR1                        Fragile X syndrome                               CRISPR/Cas9          DNA                          In       *In vitro*           Waisman Center                                         USA           ^[@bib74]^
                                PD-1                        Gastric cancer, melanoma                         CRISPR/Cas9          DNA                          Del      *In vitro*           Medical School of Nanjing University                   China         ^[@bib75]^
                                EPHA1                       Colorectal cancer                                CRISPR/Cas9          DNA                          Del      *In vitro*           Cardiff University School of Medicine                  UK            ^[@bib76]^
                                DMD                         Duchenne muscular dystrophy                      CRISPR/Cas9          DNA                          In/Del   *In vivo*            The Ohio State University Wexner Medical Center        USA           ^[@bib12]^
                                DMD                         Duchenne muscular dystrophy                      CRISPR/Cas9          DNA                          In/Del   *In vivo*            University of California                               USA           ^[@bib77]^
                                AAVS1 locus                 Chronic granulomatous disease                    ZFN                  mRNA                         In/Del   *In vivo*            National Institutes of Health                          USA           ^[@bib20]^
                                HBB                         Sickle cell disease                              ZFN                  mRNA                         In/Del   *In vivo*            University of California                               USA           ^[@bib21]^
                                CCR5                        HIV                                              ZFN                  DNA                          Del      *In vivo*            University of Southern California                      USA           ^[@bib13]^
                                HBB                         Sickle cell disease                              ZFN                  DNA                          In/Del   *In vitro*           Stanford University School of Medicine                 USA           ^[@bib78]^
                                CCR5                        HIV                                              ZFN                  DNA                          Del      *In vitro*           Lerdsin General Hospital                               Thailand      ^[@bib79]^
                                HBB                         β-Thalassemia                                    TALEN                DNA                          In/Del   *In vitro*           Guangzhou Institutes of Biomedicine and Health         China         ^[@bib80]^
                                AR                          Prostate cancer                                  TALEN                DNA                          Del      *In vitro*           Masonic Cancer Center                                  USA           ^[@bib81]^
                                COL7A1                      Recessive dystrophic epidermolysis bullosa       TALEN                DNA or mRNA                  In/Del   *In vitro*           University of Minnesota                                USA           ^[@bib19]^
                                F8                          Hemophilia A                                     TALEN                DNA                          In/Del   *In vitro*           Severance Biomedical Research Institute                Korea         ^[@bib82]^
                                PKLR                        Pyruvate kinase deficiency                       TALEN                DNA                          In/Del   *In vitro*           Centro de Investigaciones Energéticas                  Spain         ^[@bib83]^
                                CCR5                        HIV                                              TALEN                mRNA                         Del      *In vitro*           University Medical Centre Hamburg-Eppendorf            Germany       ^[@bib22]^
                                DMD                         Duchenne muscular dystrophy                      ZFN                  DNA                          In/Del   *In vivo*            Duke University                                        USA           ^[@bib84]^
                                HBB                         β-Thalassemia                                    CRISPR/Cas9          DNA                          In/Del   *In vitro*           Guangzhou Medical University                           China         ^[@bib85]^
                                CCR5                        HIV                                              CRISPR/Cas9          Protein                      In/Del   *In vitro*           Seoul National University                              Korea         ^[@bib23]^
                                NOX2                        X-linked chronic granulomatous disease           TALEN                DNA                          In       *In vitro*           Hannover Medical School                                Germany       ^[@bib86]^
  Polymers                      CCR5                        HIV                                              ZFN                  DNA                          Del      *In vitro*           State Key Laboratory of Respiratory Disease            China         ^[@bib49]^
                                E6, E7                      Cervical cancer                                  TALEN                DNA                          Del      *In vitro*           Huazhong University of Science and Technology          China         ^[@bib50]^
                                E7                          Cervical cancer                                  ZFN                  DNA                          Del      *In vivo*            Huazhong University of Science and Technology          China         ^[@bib51]^
                                HBB                         Sickle cell anemia                               TALEN                DNA                          In/Del   *In vitro*           University of Illinois                                 USA           ^[@bib52]^
  Liposomes                     HBV genome                  HBV                                              CRISPR/Cas9          DNA                          Del      *In vivo*            Soochow University                                     China         ^[@bib43]^
                                HBV genome                  HBV                                              CRISPR/Cas9          DNA                          Del      *In vitro*           Tongji University                                      China         ^[@bib44]^
                                HBV genome                  HBV                                              ZFN                  DNA                          Del      *In vitro*           Drew University                                        USA           ^[@bib45]^
                                CCR5                        HIV                                              ZFN                  DNA                          Del      *In vitro*           Universitat Auto-noma de Barcelona                     Spain         ^[@bib46]^
                                HMGB1                       Bladder Urothelial Carcinoma                     TALEN                DNA                          Del      *In vitro*           Loudi Central Hospital of Hunan Province               China         ^[@bib47]^
                                CFTR                        Cystic Fibrosis                                  ZFN                  DNA                          In/Del   *In vitro*           University College Cork                                Ireland       ^[@bib48]^
                                EGFP                        N/A                                              CRISPR/Cas9, TALEN   Protein                      Del      *In vivo*            Harvard University                                     USA           ^[@bib24]^
                                EGFP                        N/A                                              CRISPR/Cas9          Protein                      Del      *In vivo*            Tufts University                                       USA           ^[@bib25]^
  Cell penetrating peptide      CCR5                        HIV                                              CRISPR/Cas9          Protein                      Del      *In vitro*           Hanyang University                                     Korea         ^[@bib26]^
                                CCR5                        HIV                                              TALEN                Protein                      Del      *In vitro*           The Scripps Research Institute                         USA           ^[@bib27]^
  Microinjection                Cdh23                       Age-related hearing loss                         CRISPR/Cas9          mRNA                         In/Del   *In vivo*            Mary Lyon Centre, MRC Harwell, Harwell, Oxford         UK            ^[@bib87]^
                                HBB                         Sickle cell anemia                               CRISPR/Cas9, TALEN   DNA                          In/Del   *In vitro*           Georgia Institute of Technology and Emory University   USA           ^[@bib88]^
  Hypothermia                   EGFP                        N/A                                              ZFN                  Protein                      Del      *In vitro*           The Scripps Research Institute                         USA           ^[@bib28]^
  Non-viral combination         Factor VIII                 Hemophilia A                                     CRISPR/Cas9          DNA                          In/Del   *In vivo*            Yonsei University College of Medicine                  Korea         ^[@bib89]^
                                E7                          Cervical cancer                                  CRISPR/Cas9          DNA                          Del      *In vitro*           Huazhong University of Science and Technology          China         ^[@bib90]^
                                FANCC                       Fanconi Anemia                                   CRISPR/Cas9          DNA                          Del      *In vitro*           Division of Blood and Marrow Transplantation           USA           ^[@bib91]^
                                PSIP1                       HIV                                              TALEN                DNA                          Del      *In vitro*           Mayo Clinic College of Medicine                        USA           ^[@bib92]^
  Viral/non-viral combination   HBB                         Sickle cell disease                              CRISPR/Cas9, TALEN   mRNA                         In/Del   *In vitro*           University of California                               USA           ^[@bib93]^
                                Fah                         Tyrosinemia                                      CRISPR/Cas9          mRNA                         In/Del   *In vivo*            Massachusetts Institute of Technology                  USA           ^[@bib94]^

###### Therapeutic gene editing in clinical trials.

  Vector                   Phases   Target gene   Disease                                              Nuclease      *Ex/In vivo*   Interventions                                                Enrollment   Country   Organization                                        NCT number
  ------------------------ -------- ------------- ---------------------------------------------------- ------------- -------------- ------------------------------------------------------------ ------------ --------- --------------------------------------------------- -------------
  Adenoviral vectors       I        CCR5          HIV                                                  ZFN           *Ex vivo*      ZFN-modified CD4+T cells                                     12           USA       University of Pennsylvania                          NCT00842634
                           I        CCR5          HIV                                                  ZFN           *Ex vivo*      ZFN-modified CD4+T cells                                     19           USA       Sangamo Biosciences                                 NCT01044654
                           I/II     CCR5          HIV                                                  ZFN           *Ex vivo*      ZFN-modified CD4+T cells                                     21           USA       Sangamo Biosciences                                 NCT01252641
                           I/II     CCR5          HIV                                                  ZFN           *Ex vivo*      ZFN-modified CD4+T cells                                     26           USA       Sangamo Biosciences                                 NCT01543152
  AAV vectors              I        Factor IX     Hemophilia B                                         ZFN           *In vivo*      ZFP-encoding rAAV(SB-FIX)                                    9            USA       Sangamo Biosciences                                 NCT02695160
                           I        IDUA          MPS I                                                ZFN           *In vivo*      ZFP-encoding rAAV (SB-318)                                   9            USA       Sangamo Biosciences                                 NCT02702115
  Electroporation (mRNA)   I        TCR-α/CD52    Relapsed/refractory B acute lymphoblastic leukemia   TALEN         *Ex vivo*      TALEN-modified CD19-CAR-T                                    10           UK        Institut de Recherches Internationales Servier      NCT02808442
                           I/II     CCR5          HIV                                                  ZFN           *Ex vivo*      ZFN-modified T cells+ cyclophosphamide                       12           USA       Sangamo Biosciences                                 NCT02225665
                           I        CCR5          HIV                                                  ZFN           *Ex vivo*      ZFN-modified CD4+T cell+ cyclophosphamide                    15           USA       University of Pennsylvania                          NCT02388594
                           I        CCR5          HIV                                                  ZFN           *Ex vivo*      ZFN-modified HSPC+busulfan                                   12           USA       City of Hope Medical Center                         NCT02500849
                           N/A      TCR-α/CD52    ALM                                                  TALEN         *Ex vivo*      TALEN-modified anti-CD19 CAR-T                               200          UK        Institut de Recherches Internationales Servier      NCT02735083
                           I        TCR-α/CD52    ALM                                                  TALEN         *Ex vivo*      TALEN-modified anti-CD19 CAR-T                               12           UK        Servier                                             NCT02746952
  Naked plasmid            I        VEGF-A        Intermittent claudication                            ZFN           *In vivo*      DNA Plasmid Vector                                           10           USA       National Heart, Lung, and Blood Institute (NHLBI)   NCT00080392
  N/A                      I        E7            HPV-related malignant neoplasm                       ZFN           *In vivo*      ZFN-603 and ZFN-758                                          20           China     Huazhong University of Science and Technology       NCT02800369
                           I        PDCD1         Metastatic Non-small cell lung cancer                CRISPR/Cas9   *Ex vivo*      CRISPR/Cas9-edited T cells+ cyclophosphamide+Interleukin-2   15           China     Sichuan University                                  NCT02793856
                           I        PDCD1         Invasive bladder cancer stage IV                     CRISPR/Cas9   *Ex vivo*      CRISPR/Cas9-edited T cells+ cyclophosphamide+interleukin-2   20           China     Peking University                                   NCT02863913
                           I        PDCD1         Metastatic renal cell carcinoma                      CRISPR/Cas9   *Ex vivo*      CRISPR/Cas9-edited T cells+ cyclophosphamide+interleukin-2   20           China     Peking University                                   NCT02867332
                           I        PDCD1         Hormone refractory prostate cancer                   CRISPR/Cas9   *Ex vivo*      CRISPR/Cas9-edited T cells+ cyclophosphamide+interleukin-2   20           China     Peking University                                   NCT02867345

ALM, Advanced Lymphoid Malignancies.

###### Relevant guidance documents for gene-editing therapeutics.

  Guidance titles                                                                                                                                                                                                              Regulatory agencies   Year
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ------
  Guidance for industry: FDA guidance for human somatic cell therapy and gene therapy                                                                                                                                          FDA                   1998
  Quality, preclinical and clinical aspects of gene transfer medicinal products                                                                                                                                                EMA                   2001
  Guideline on development and manufacture of lentiviral vectors                                                                                                                                                               EMA                   2005
  Guidance for industry: gene therapy clinical trials-observing participants for delayed adverse events                                                                                                                        FDA                   2006
  Guidance for industry: supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors   FDA                   2006
  Guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectors                                                                                                                             EMA                   2007
  Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer                                                                                                                      EMA                   2007
  Guidance for FDA reviewers and sponsors: content and review of chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs)                                   FDA                   2008
  Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products                                                                                                                  EMA                   2008
  Guideline on human cell-based medicinal products                                                                                                                                                                             EMA                   2008
  Guideline on safety and efficacy follow-up- risk management of advanced therapy medicinal products                                                                                                                           EMA                   2008
  ICH consideration oncolytic viruses                                                                                                                                                                                          EMA                   2009
  Follow-up of patients administered with gene therapy medicinal products                                                                                                                                                      EMA                   2009
  Quality, non-clinical and clinical issues relating specifically to recombinant adeno-associated viral vectors                                                                                                                EMA                   2010
  Guideline on the minimum quality and non-clinical data for certification of advanced therapy medicinal products                                                                                                              EMA                   2010
  Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use                                                                                                                            EMA                   2010
  Guidance for industry: potency test for cellular and gene therapy products                                                                                                                                                   FDA                   2011
  Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells                                                                                                          EMA                   2012
  Preclinical assessment of investigational cellular and gene therapy products                                                                                                                                                 FDA                   2013
  Guideline on the risk-based approach according to annex I, part IV of directive 2001/83/EC applied to advanced therapy medicinal products                                                                                    EMA                   2013
  Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues                                                                           EMA                   2013
  Management of clinical risks deriving from insertional mutagenesis                                                                                                                                                           EMA                   2013
  Guidance of industry: considerations for the design of early-phase clinical trials of cellular and gene therapy products                                                                                                     FDA                   2015
